COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

570 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2026-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite significant advances in patient blood management, cardiac surgery remains a surgical procedure at high risk for bleeding. Numerous perioperative blood conservation strategies have been developed for limiting the use of blood products. Among them, the processing of shed blood and residual cardiopulmonary bypass circuit volume with autotransfusion device is routinely used. Conventional centrifugation-based autotransfusion devices actually available only recover red blood cells while platelets and coagulation factors are almost totally lost. Consequently, large amounts of intraoperative cell salvage could significantly alter perioperative haemostasis. The SAME autotransfusion device (i-SEP, France) is a new and innovative filtration-based autotransfusion device able to recover erythrocytes, leukocytes but also platelets. By offering the opportunity to re-infuse to patients their own platelets in addition red blood cells, significantly improve perioperative haemostasis with this new device is expected. The purpose of the COLTRANE trial is to compare the quality of the perioperative haemostasis in cardiac surgical patients for whom intraoperative cell salvage will be performed using either the SAME autotransfusion device or conventional centrifugation-based device.

Because allogenic transfusion of blood products as well as surgical re-exploration for excessive bleeding are associated with poor outcomes and prolonged length of stay, the use of filtration-based SAME device by maintaining perioperative haemostasis could improve outcomes and reduce length of stay of high risk patients. The fact that patients receive their own platelets should also limit the risk of allo-immunization and immunomodulation which is recognized as one of the underlying mechanisms of perioperative increased risk of infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery

NCT04588350

Hemorrhage Blood Loss Surgical Blood Loss

COMPLETED NA

Platelet and Autotransfusion Device in Cardiac Surgery

NCT06629311

Platelets Autotransfusion Device

RECRUITING

Comparison of the Performance and Effectiveness of Two Transfusion-Saving Devices: Cell-Saver and SAME

NCT06766032

Cardiac Surgery Under Extra Corporeal Circulation Cardiac Surgery Requiring Cardiopulmonary Bypass

COMPLETED

Perioperative Coagulation Management in Cardiac Surgery.

NCT00772239

Cardiac Surgery Bleeding

TERMINATED NA

The Transfusion Triggers in Vascular Surgery Trial

NCT02465125

Atherosclerosis Anemia Aortic Aneurysm, Abdominal +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SAME device is a new and innovative filtration-based autotransfusion device able to recover both erythrocytes and platelets. A multicentre single-arm clinical feasibility and safety trial conducted by our group, using SAME device on 50 cardiac surgical patients reported erythrocyte yield per cycle of 89%, post-treatment hematocrit of 43% with an excellent washing performance. In addition, the device recovered 52% of platelets, that were found unaltered by the device as demonstrated by a limited platelet activation and a strong response to thrombin-pathway stimulation assessed by flow cytometry. By offering the opportunity to re-infuse to the patients their own platelets in addition to their RBC, this new device might significantly improve perioperative haemostasis and thus decrease the need for blood products. It is well established that severe postoperative bleeding and blood products transfusion lead to increase morbidity and mortality. Consequently, an improvement of postoperative outcomes and a decrease in intensive care unit (ICU) and hospital length of stay may be expected. The fact that patients receive their own platelets should limit the risk of allo-immunization and immunomodulation which is recognized as one of the underlying mechanisms of perioperative increased risk of infection. Consequently, a reduction of infectious complication may be also expected.

The purpose of COLTRANE trial is to test the hypothesis that the intraoperative use of the filtration-based SAME autotransfusion device could improve perioperative haemostasis thereby reducing the proportion of patients exhibiting clinically significant perioperative bleeding (moderate to massive bleeding according the Universal Definition of Perioperative Bleeding (UDPB) classification).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

On-pump Cardiac Surgery High Risk for Bleeding Autotransfusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicentre clinical trial, Randomized, Comparative, controlled, single blinded, superiority design, two groups.

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Autotransfusion by filtration

new filtration-based autotransfusion (SAME I-SEP device)

Group Type EXPERIMENTAL

Autotransfusion

Intervention Type PROCEDURE

ANTIFIBRINOLYTIC THERAPY :

tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end

INTRAOPERATIVE MANAGEMENT :

* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter
* The general anaesthesia :
* propofol and Remifentanil or sufentanil both simultaneously administered .
* monitoring of the bispectral index
* Triple lumen central venous catheter
* Heparinization (300 UI/kg)
* Aortic and right auricular cannulations

TRANSFUSION PROTOCOL :

* During CPB, PRBC transfusion if necessary
* In the postoperative period if necessary

In bleeding patients:

The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.

Autotransfusion by centrifugation

centrifugation-based autotransfusion (routinely used in cardiac surgery centers)

Group Type OTHER

Autotransfusion

Intervention Type PROCEDURE

ANTIFIBRINOLYTIC THERAPY :

tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end

INTRAOPERATIVE MANAGEMENT :

* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter
* The general anaesthesia :
* propofol and Remifentanil or sufentanil both simultaneously administered .
* monitoring of the bispectral index
* Triple lumen central venous catheter
* Heparinization (300 UI/kg)
* Aortic and right auricular cannulations

TRANSFUSION PROTOCOL :

* During CPB, PRBC transfusion if necessary
* In the postoperative period if necessary

In bleeding patients:

The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autotransfusion

ANTIFIBRINOLYTIC THERAPY :

tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end

INTRAOPERATIVE MANAGEMENT :

* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter
* The general anaesthesia :
* propofol and Remifentanil or sufentanil both simultaneously administered .
* monitoring of the bispectral index
* Triple lumen central venous catheter
* Heparinization (300 UI/kg)
* Aortic and right auricular cannulations

TRANSFUSION PROTOCOL :

* During CPB, PRBC transfusion if necessary
* In the postoperative period if necessary

In bleeding patients:

The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adult patients (≥18 yr) affiliated or beneficiary of a social security scheme and undergoing on-pump cardiac surgery at high risk for bleeding with autotranfusion indication defined as:

* Primary or redo combined cardiac procedures (2 valves or more, valve(s) and coronary artery bypass grafting(s))
* Primary or redo ascending aorta surgery
* Primary or redo isolated coronary artery bypass grafting (iCABG) involving 3 or more grafts using the internal mammary artery
* Free, informed and written consent signed by the participant and the investigator

Exclusion Criteria

* Preoperative therapy by P2Y12 receptor inhibitors (within 5 preoperative days for clopidogrel, ticagrelor or ticlopidine, within 7 preoperative days for prasugrel, and within one preoperative hour for cangrelor)
* Preoperative treatment by active anticoagulant drug (within 5 preoperative days for VKA, 4 days for dabigatran, 3 days for rivaroxaban and apixaban, 24 hours for therapeutic LMWH, 36 hours for therapeutic fondaparinux, 12 hours for prophylactic LMWH, 24 hours for prophylactic fondaparinux, 4 hours for unfractionated heparin Sepsis
* Malignant tumor
* Immunocompromised patients (steroids, immunosuppressive drugs, ongoing treatment for solid tumor or hematologic malignancy, primary immunodeficiency disorders, AIDS)
* Emergency cardiac surgery
* Heart transplantation
* Implantation or patients under ventricular assist device (VAD)
* Patients with two or more previous sternotomy
* Surgery procedure requiring circulatory arrest and/or profound hypothermia (\<32°C)
* Active infective endocarditis
* Cardiac surgical procedure for benign or malignant cardiac tumors
* Patients with known acquired or constitutional coagulopathy requiring specialist management
* End stage renal disease
* Preoperative haemoglobin level less than 10 g/dL
* Preoperative platelet count \< 100 G/L
* Persons participating in another interventional research including a period of exclusion that is still ongoing
* Pregnant or breastfeeding women
* Persons placed under judicial protection
* Patients deprived of liberty

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No